Abstract: A rigid-flexible substrate includes a plurality of rigid portions, and a flexible portion connecting the plurality of rigid portions and including a portion of a first resin sheet including at least one layer of a thermoplastic resin sheet, the rigid portions including a portion of the first resin sheet other than the flexible portion, and a second resin sheet including a plurality of thermoplastic resin sheets laminated on one surface or both surfaces of the portion of the first resin sheet other than the flexible portion, and a tapered portion is provided at an end edge of the second resin sheet on a side close to the flexible portion, and a thickness of the tapered portion in a direction in which the second resin sheet is laminated decreases toward the flexible portion and is substantially 0 at a position in contact with the flexible portion.

Abstract: A rigid-flexible substrate includes a plurality of rigid portions, and a flexible portion connecting the plurality of rigid portions and including a portion of a first resin sheet including at least one layer of a thermoplastic resin sheet, the rigid portions including a portion of the first resin sheet other than the flexible portion, and a second resin sheet including a plurality of thermoplastic resin sheets laminated on one surface or both surfaces of the portion of the first resin sheet other than the flexible portion, and a tapered portion is provided at an end edge of the second resin sheet on a side close to the flexible portion, and a thickness of the tapered portion in a direction in which the second resin sheet is laminated decreases toward the flexible portion and is substantially 0 at a position in contact with the flexible portion.

Abstract: This invention provide to a pharmaceutical composition for treating spinocerebellar ataxia (or atrophy, degeneration) or multiple system atrophy, or for improving ataxia or equilibrium disturbance comprising a compound of the formula (I): wherein R is methyl, cyano or carbamoyl, a pharmaceutically acceptable salt, or a solvate thereof as an active ingredient.

Abstract: A multilayer circuit board includes a laminate having a plurality of ceramic layers, and a wiring pattern disposed in the laminate, wherein a ceramic layer includes, as the wiring pattern, a fully penetrating via-hole conductor that vertically passes through the ceramic layers, and a serial partially penetrating via-hole conductor that is electrically connected to the fully penetrating via-hole conductor in the ceramic layers and does not pass completely through the ceramic layers.

Abstract: A multilayer circuit board includes a laminate having a plurality of ceramic layers, and a wiring pattern disposed in the laminate, wherein a ceramic layer includes, as the wiring pattern, a fully penetrating via-hole conductor that vertically passes through the ceramic layers, and a serial partially penetrating via-hole conductor that is electrically connected to the fully penetrating via-hole conductor in the ceramic layers and does not pass completely through the ceramic layers.

Abstract: This invention provide to a pharmaceutical composition for treating spinocerebellar ataxia (or atrophy, degeneration) or multiple system atrophy, or for improving ataxia or equilibrium disturbance comprising a compound of the formula (I): wherein R is methyl, cyano or carbamoyl, a pharmaceutically acceptable salt, or a solvate thereof as an active ingredient.

Abstract: The present invention provides a percutaneously administrable preparation comprising either an aqueous base comprising 1-menthol, a lower alcohol and an acidic buffer or water, or an oily base comprising 1-menthol, a lower alcohol and isopropyl myristate, and a cerebral function activator, for example, 2-(3-isoxazolyl)-3,6,7,9-tetrahydroimidazo[4,5-d]pyrano[4,3-b]pyridine, pharmaceutically acceptable salt or hydrate thereof.

Abstract: The present invention provides enteric coated preparation excellent in absorbability, containing thyrotropin-releasing hormone (TRH) or derivatives thereof as a medicinally active ingredient.

Abstract: The present invention provides an oil preparation comprising a high lipophilic medicament such as a compound of the formula (I): 1

Abstract: A peptide derivation of the formula (I) or its pharmaceutically acceptable salt or hydrate thereof is disclosed. These compounds have superior ability over thyroid stimulating hormone (TRH) and its derivatives to activate the central nervous system, such as, for example, sustained acetylcholine releasing action, anti-reserpine action and locomotor increment.